Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gene editing
Biotech
CRISPR Tx sees 80% fall in LDL, triglycerides after in vivo edit
CRISPR Tx reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310.
Nick Paul Taylor
May 7, 2025 10:00am
Nonprofit nets $10M to build fungal research resources
Apr 24, 2025 7:00am
Cell and gene company ElevateBio lays off 17% of staff
Mar 26, 2025 1:08pm
Vertex axes Verve gene editing pact amid shift in R&D priorities
Feb 27, 2025 9:05am
It's curtain close for Spotlight: Gene editing biotech shutters
Feb 19, 2025 4:28pm
Gene editor Scribe slims down workforce as it readies for clinic
Jan 8, 2025 5:33pm
